 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- | DiaPep277 / Horizon Therapeutics, Evotec
Journal: Plasmodium falciparum FIKK9.1 is a monomeric serine-threonine protein kinase with features to exploit as a drug target. (Pubmed Central) - Oct 14, 2021
Correlation analysis of peptides from the combinatorial library concluded that peptide P277 (MFDFHYTLGPMWGTL) was fitting nicely into the binding pocket...Interestingly, FIKK9.1 is phosphorylating spectrin, ankyrin, and band-3 from RBC cytoskeleton. Our study highlights the structural and biochemical features of FIKK9.1 to exploit it as a drug target.
- | DiaPep277 / Evotec, Amgen
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: The Safety and Efficacy of Administrating DiaPep277 (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=0, Withdrawn, Sponsor: Hadassah Medical Organization
Our study highlights the structural and biochemical features of FIKK9.1 to exploit it as a drug target. N=20 --> 0 | Initiation date: Aug 2013 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2014 --> Jan 2016
- DiaPep277 / Evotec, Amgen
Enrollment closed: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 (clinicaltrials.gov) - Jul 28, 2013
P3, N=11, Active, not recruiting, Sponsor: Rabin Medical Center
N=20 --> 0 | Initiation date: Aug 2013 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2014 --> Jan 2016 Recruiting --> Active, not recruiting
- |||||||||| DiaPep277 / Evotec, Amgen
New P3 trial: DIA-AID 2: Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 (clinicaltrials.gov) - Jul 10, 2013
P3, N=300, Not yet recruiting, Sponsor: Andromeda Biotech Ltd.
- ||||| DiaPep277 / Evotec, Amgen
Enrollment closed: DIA-AID2: Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (clinicaltrials.gov) - Jul 9, 2013
P3, N=450, Active, not recruiting, Sponsor: Andromeda Biotech Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || DiaPep277 / Evotec, Amgen
Trial completion: Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes (clinicaltrials.gov) - Jul 9, 2013
P3, N=43, Completed, Sponsor: Andromeda Biotech Ltd.
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- ||||||| DiaPep277 / Evotec, Amgen
Trial completion: DIA-AID: Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (clinicaltrials.gov) - Jul 9, 2013
P3, N=457, Completed, Sponsor: Andromeda Biotech Ltd.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- DiaPep277 / Evotec, Amgen
New P1/2 trial: The Safety and Efficacy of Administrating DiaPep277 (clinicaltrials.gov) - Jun 18, 2013
P1/2, N=20, Not yet recruiting, Sponsor: Hadassah Medical Organization
- DiaPep277 / Evotec, Amgen
Trial initiation date: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 (clinicaltrials.gov) - Dec 27, 2011
P3, N=11, Active, not recruiting, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Jan 2012
- DiaPep277 / Evotec, Amgen
New P3 trial: OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 (clinicaltrials.gov) - Oct 24, 2011
P3, N=11, Active, not recruiting, Sponsor: Rabin Medical Center